TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8706291

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patches, 0.05 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subdermal implants containing 50 mg oestradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subdermal implants containing 50 mg oestradiol with 100 mg testosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestradiol implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women with ovaries)
Number of subjects: 0
Study: 1647495

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: 8 mg sumatriptan
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg or 8 mg)
Number of subjects: 639
Study: 6849778

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31242976

Group type: EXPERIMENTAL
Intervention: Cisplatin (Arm A) - 100 mg/m² 3-weekly or 40 mg/m² weekly during radiation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cetuximab (Arm B) - loading dose 400 mg/m² one week before radiation followed by 250 mg/m² weekly during radiation
Number of subjects: 40
Study: 29851894

Group type: EXPERIMENTAL
Intervention: Receiving a Section 8 housing voucher
Number of subjects: 0
Study: 27422360

Group type: EXPERIMENTAL
Intervention: Internal suture ligation (IL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: External stapled excision (StEx)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Surgical excision (SxEx)
Number of subjects: 28
Study: 25344383

Group type: EXPERIMENTAL
Intervention: Acitretin (30 mg per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20974089

Group type: EXPERIMENTAL
Intervention: Tai Chi (n=6), attended classes once a week and practiced 10 minutes daily for 15 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (n=5), received no intervention
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tai Chi (n=6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 11
Study: 21088457

Group type: COMPARATOR
Intervention: Open Bankart repair
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 64
Study: 18223016

Group type: EXPERIMENTAL
Intervention: rTMS at 10 Hz (subthreshold)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham rTMS at 10 Hz
Number of subjects: 46
Study: 15807740

Group type: EXPERIMENTAL
Intervention: Topical adapalene gel (0.1%)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Topical metronidazole gel (0.75%)
Number of subjects: 55
Study: 12911186

Group type: EXPERIMENTAL
Intervention: Selective Estrogen Receptor Modulators (SERMs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (Clomid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 11091218

Group type: EXPERIMENTAL
Intervention: G-CSF (1 microg/kg and 5 microg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg/kg b.i.d)
Number of subjects: 8
Study: 9248767

Group type: EXPERIMENTAL
Intervention: 20 mg racemic nicardipine (conventional preparation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg racemic nicardipine (conventional preparation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg sustained-release nicardipine
Number of subjects: 8
Study: 8287938

Group type: EXPERIMENTAL
Intervention: Nebulized amiloride, administered four times daily for two six month periods
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo, administered four times daily for two six month periods
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nebulized amiloride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3826597

Group type: EXPERIMENTAL
Intervention: Indomethacin (rectal administration)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 29872288

Group type: EXPERIMENTAL
Intervention: GB 6.25 μg BID
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: GB 12.5 μg BID
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: GB 25 μg BID
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: GB 50 μg BID
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 28387543

Group type: EXPERIMENTAL
Intervention: 4-AP 10 mg extended release
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26147790

Group type: EXPERIMENTAL
Intervention: Swedish indicator set
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: French indicator set
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: German indicator set
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gold standard assessment
Number of subjects: 200
Study: 24264227

Group type: EXPERIMENTAL
Intervention: Diet A (gluten-free products with purified oats)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet B (gluten-free products with placebo)
Number of subjects: 0
Study: 21466389

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) 5/80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 0
Study: 18543485

Group type: EXPERIMENTAL
Intervention: Huanglan Granule (HLG) - one dosage per day, containing milkvetch root, isatis root and basket fern, each 30 g
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ribavirin - 0.2 g, three times per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Huanglan Granule (HLG)
Number of subjects: 60
Study: 16864837

Group type: EXPERIMENTAL
Intervention: Idiopathic generalized epilepsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Localization-related epilepsy
Number of subjects: 0
Study: 12482764

Group type: EXPERIMENTAL
Intervention: Single caffeine dose (6 mg/kg) 60 min before exercise and placebo 45 min into exercise (CP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Divided caffeine dose (3 mg/kg) 60 min before and 45 min into exercise (CC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo 60 min before and 45 min into exercise (PP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Divided caffeine dose (3 mg/kg) (CC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single caffeine dose (6 mg/kg) (CP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine doses (CP and CC)
Number of subjects: 9
Study: 10685094

Group type: EXPERIMENTAL
Intervention: Variable pulse Er:YAG laser
Number of subjects: 21

Group type: COMPARATOR
Intervention: CO2 laser resurfacing
Number of subjects: 21
Study: 9332313

Group type: EXPERIMENTAL
Intervention: Deferiprone (L1; CP020)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Desferrioxamine (DFO)
Number of subjects: 57
Study: 8437152

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 31517512

Group type: EXPERIMENTAL
Intervention: REDCHiP intervention
Number of subjects: 43
Study: 31843831

Group type: EXPERIMENTAL
Intervention: Learning Clubs programme
Number of subjects: 1008
Study: 28884132

Group type: EXPERIMENTAL
Intervention: Telbivudine-replacement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lamivudine-continuous
Number of subjects: 120
Study: 27037633

Group type: EXPERIMENTAL
Intervention: Short form of ASSIST comprising three items (past‐3‐month frequency of use, urge to use, and whether others have expressed concern for use)
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Factor analysis of tobacco, alcohol, and cannabis items
Number of subjects: 2599
Study: 24812543

Group type: EXPERIMENTAL
Intervention: Fish (Atlantic salmon) three times per week from September to February
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (alternative meal such as chicken, pork, beef with the same nutritional value) three times per week from September to February
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fish group vitamin D status
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: HRV
Number of subjects: 95
Study: 22992610

Group type: EXPERIMENTAL
Intervention: 80 kVp protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: 120 kVp protocol
Number of subjects: 100
Study: 20502757

Group type: EXPERIMENTAL
Intervention: Trans-septal sutures using a novel device
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nasal packing with a tampon
Number of subjects: 64
Study: 18284032

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 400 mg per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (calcium gluconate 400 mg per day)
Number of subjects: 30
Study: 16269645

Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: DWI reversal in tPA patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Acute DWI region that infarcted
Number of subjects: 26
Study: 11865843

Group type: EXPERIMENTAL
Intervention: Rapid dipstick assay for the detection of Salmonella typhi‐specific IgM antibodies
Number of subjects: 127
Study: 10218094

Group type: EXPERIMENTAL
Intervention: Neurogenic bladder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal bladder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obstructed bladder
Number of subjects: 0
Study: 7793871

Group type: EXPERIMENTAL
Intervention: Cefodizime (50 mg/kg once daily for 10 +/- 3 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg once daily for 10 +/- 3 days)
Number of subjects: 30
Study: 2228655

Group type: EXPERIMENTAL
Intervention: In-hospital and postdischarge nursing interventions
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 67
Study: 345173

Group type: EXPERIMENTAL
Intervention: Photocoagulation treatment
Number of subjects: 0
Study: 31656179

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with targeted sedation using processed electroencephalogram monitoring
Number of subjects: 218

Group type: COMPARATOR
Intervention: General anesthesia without processed electroencephalogram monitoring
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with targeted sedation
Number of subjects: 218

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 218
Study: 29468508

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 0.25% bupivacaine plus tizanidine 6 mg capsule (Group SC+T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 0.25% bupivacaine (Group SC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 0.9% saline plus oral placebo (Group C)
Number of subjects: 60
Study: 26743709

Group type: EXPERIMENTAL
Intervention: Regular telephone-based care and three home visits from a health professional over 2 years
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard care (no regular contact with health professionals)
Number of subjects: 410
Study: 25439973

Group type: EXPERIMENTAL
Intervention: Multidisciplinary parent education program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 42
Study: 21901320

Group type: EXPERIMENTAL
Intervention: Donepezil (0.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil (1.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine (0.3 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg)
Number of subjects: 0
Study: 18843179

Group type: EXPERIMENTAL
Intervention: Spaced retrieval
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard rehearsal
Number of subjects: 30
Study: 16736148

Group type: EXPERIMENTAL
Intervention: Gamma trochanteric nail
Number of subjects: 112

Group type: COMPARATOR
Intervention: ACE trochanteric nail
Number of subjects: 112
Study: 15173845

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11120963

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 120 mg by injection (group 1 and group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 240 mg by infusion (group 3)
Number of subjects: 30
Study: 9766341

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study: 8137478

Group type: COMPARATOR
Intervention: 4'-epidoxorubicin (70 mg) alone (group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lipiodol emulsion with 4'-epidoxorubicin (70 mg) (group B)
Number of subjects: 36
Study: 2530761

Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg/day (titrated between 10 and 50mg/day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 111
Study: 1094970

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cholecystectomy with midline incision
Number of subjects: 54

Group type: COMPARATOR
Intervention: Small bowel bypass without cholecystectomy
Number of subjects: 54
Study: 31593088

Group type: EXPERIMENTAL
Intervention: Bronchial blockers (BB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Double-lumen bronchial tubes (DLBT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 28903738

Group type: EXPERIMENTAL
Intervention: GM-PA (goal-setting and behavioral education workshops with mentor support via telephone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CO-PA (standard education workshops and Physical Activity Liaison contact via telephone)
Number of subjects: 100
Study: 26031368

Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine combined with oxaliplatin (CAPOX) followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab (part of the intervention group).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 0
Study: 24378824

Group type: EXPERIMENTAL
Intervention: Urinary calprotectin concentrations in bladder cancer patients (522.3 ng/ml)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Calprotectin concentrations in low grade tumors (351.9 ng/ml)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for urinary calprotectin
Number of subjects: 181
Study: 21899798

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis (BB-12®)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei (L. casei 431®)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 19283996

Group type: EXPERIMENTAL
Intervention: Verhaltenstraining fur Schulanfanger (intervention)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 17126335

Group type: EXPERIMENTAL
Intervention: Oxiplex/AP gel treatment (treated group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 37
Study: 15709663

Group type: EXPERIMENTAL
Intervention: Spatiotemporal blind source separation (BSS) algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent component analysis (ICA) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatiotemporal BSS algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICA method
Number of subjects: 0
Study: 12505246

Group type: EXPERIMENTAL
Intervention: Respondents (those who participated in the trial)
Number of subjects: 112528

Group type: EXPERIMENTAL
Intervention: Willing respondents (those who agreed to participate)
Number of subjects: 112528

Group type: EXPERIMENTAL
Intervention: Eligible respondents (those who completed a run-in phase and were randomized)
Number of subjects: 112528

Group type: EXPERIMENTAL
Intervention: Men completing a run-in and randomized into PHS
Number of subjects: 112528
Study: 10592423

Group type: EXPERIMENTAL
Intervention: Parenteral fluids with diazepam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Parenteral fluids without diazepam (control group)
Number of subjects: 50
Study: 7856522

Group type: EXPERIMENTAL
Intervention: Rotational angioplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional angioplasty
Number of subjects: 100
Study: 1765205

Group type: EXPERIMENTAL
Intervention: PGE2 pessaries (2.5 mg) 1‐2 a day
Number of subjects: 125

Group type: COMPARATOR
Intervention: PGE2 (0.5 mg) in a viscous intracervical gel once daily
Number of subjects: 125
Study: 6812230

Group type: EXPERIMENTAL
Intervention: 3% amino acids with 3% glycerol
Number of subjects: 2

Group type: COMPARATOR
Intervention: 3% amino acids
Number of subjects: 2
Study: 31780429

Group type: EXPERIMENTAL
Intervention: Back massage (twice per day in the morning and evening)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 84
Study: 30611335

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 53
Study: 28176487

Group type: EXPERIMENTAL
Intervention: Lornoxicam Immediate-Release Tablets (8 mg/tablet)
Number of subjects: 30
Study: 25813356

Group type: EXPERIMENTAL
Intervention: Auto servo-ventilation (ASV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASV manual (PSmin 6)
Number of subjects: 0
Study: 23562228

Group type: EXPERIMENTAL
Intervention: Optokinetic training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21093035

Group type: EXPERIMENTAL
Intervention: Experimental ormocer (ORM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercial mixed dimethacrylate‐ormocer‐based matrix (Admira (ADR))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercial dimethacrylate‐based matrix composites (Grandio (GRD) and Premise (PRE))
Number of subjects: 20
Study: 19205956

Group type: EXPERIMENTAL
Intervention: Aquatic physical activity intervention (8-week programme, 24 sessions)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vocational rehabilitation class (control group, 8-week programme, 24 sessions)
Number of subjects: 16
Study: 17687149

Group type: EXPERIMENTAL
Intervention: Weekly bolus CPT‐11 plus FU plus LV
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Weekly bolus FU plus LV (control)
Number of subjects: 1264
Study: 14694457

Group type: COMPARATOR
Intervention: Tolterodine 2 mg bid (Ta)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid plus PFME (Tp)
Number of subjects: 480
Study: 11405384

Group type: EXPERIMENTAL
Intervention: 12.5 mg rofecoxib
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 1500 mg nabumetone
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 9990362

Group type: EXPERIMENTAL
Intervention: Cyclosporin at an initial dose of 1 mg/kg per day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 7835207

Group type: EXPERIMENTAL
Intervention: Glycemic control intervention during a 2-week admission
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 34
Study: 3189161

Group type: EXPERIMENTAL
Intervention: Neoprene barrier liner
Number of subjects: 8

Group type: COMPARATOR
Intervention: GORE-TEX barrier liner
Number of subjects: 8
Study: 29866383

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Residential Treatment (RT)
Number of subjects: 113
Study: 27592119

Group type: EXPERIMENTAL
Intervention: Diabetic ketosis
Number of subjects: 972

Group type: COMPARATOR
Intervention: Non-ketotic hyperglycemia
Number of subjects: 972
Study: 23670354

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg daily for 12 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 23361631

Group type: EXPERIMENTAL
Intervention: Computer-driven protocol (Smartcare/PS™, Drager Medical)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (no protocolized decisions by attending physicians)
Number of subjects: 30
Study: 21107585

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (nutrition and exercise counseling)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group-based treatment (GT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal-weight children (control group)
Number of subjects: 61
Study: 19473604

Group type: COMPARATOR
Intervention: Brethmol (4 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ventolin (4 mg)
Number of subjects: 22
Study: 16499533

Group type: EXPERIMENTAL
Intervention: Fetal screening for Down syndrome by ultrasound examination (including measurement of fetal nuchal translucency) at 12 to 14 weeks' gestation.
Number of subjects: 24
Study: 14982045

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%/Timolol 0.5% combination (COSOPT) eye drops twice daily
Number of subjects: 544

Group type: COMPARATOR
Intervention: Latanoprost 0.005% (XALATAN) eye drops once daily
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 544
Study: 11334097

Group type: EXPERIMENTAL
Intervention: Core warming with the Hotline Fluid Warmer (Sims Level 1, Inc., Rockland, MA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Peripheral warming with the Snuggle Warm Convective Warming System (Sins Level 1, Inc., Rockland, MA)
Number of subjects: 8